A
Alain M. Schoepfer
Researcher at University Hospital of Lausanne
Publications - 321
Citations - 16599
Alain M. Schoepfer is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Eosinophilic esophagitis & Medicine. The author has an hindex of 51, co-authored 265 publications receiving 13251 citations. Previous affiliations of Alain M. Schoepfer include University of Zurich & McMaster University.
Papers
More filters
Journal ArticleDOI
Addressing current treatment challenges in Crohn's disease in real life: A physician's survey
Stephan R. Vavricka,Sanja Radivojevic,Christine N. Manser,Pascal Frei,Emanuel Burri,Michael Fried,Alain M. Schoepfer,Laurent Peyrin-Biroulet,Pierre Michetti,Gerhard Rogler,Luc Biedermann +10 more
TL;DR: Everyday clinical practice in Crohn's disease patients appears to be incongruent with clinical data derived from major trials, and studies investigating reasons underlying these discrepancies are of need to optimize and harmonize treatment.
Journal ArticleDOI
Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6‐week open‐label trial of the EOS‐2 Programme
Stephan Miehlke,Christoph Schlag,Alfredo J. Lucendo,Luc Biedermann,Cecilio Santander Vaquero,Christoph Schmoecker,Jamal O. Hayat,Petr Hruz,Constanza Ciriza de los Ríos,Albert J. Bredenoord,Michael Vieth,Alain M. Schoepfer,Stephen Attwood,Ralph Mueller,Sarah Burrack,Roland Greinwald,Alex Straumann +16 more
TL;DR: In this large prospective trial, a 6‐week open‐label treatment with BOT 1 mg BID was highly effective and safe in achieving clinico‐histological remission of active EoE and confirmed the results of the placebo‐controlled EOS‐1 trial.
Journal ArticleDOI
Eosinophilic Esophagitis: Impact of Latest Insights Into Pathophysiology on Therapeutic Strategies.
TL;DR: This review highlights the latest insights regarding pathophysiology and its impact regarding current and future therapeutic strategies and the therapeutic options can be summarized with the 3 D's, which stand for drugs, diets and dilation.
Journal ArticleDOI
The ‘Red Flag Instrument’ for Early Detection of Crohn’s Disease: Is It ready for Clinical Practice?
TL;DR: Length of diagnostic delay can indeed represent an issue for at least a proportion of patients with Crohn’s disease [CD].
Journal ArticleDOI
Lower Risk of B1-to-pB3-Stage Migration in Crohn’s Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study
Patrick S Cernoch,Nicolas Fournier,Jonas Zeitz,Michael Scharl,Bernhard Morell,Thomas Greuter,Philipp Schreiner,Benjamin Misselwitz,Ekaterina Safroneeva,Alain M. Schoepfer,Stephan R. Vavricka,Gerhard Rogler,Luc Biedermann +12 more
TL;DR: The data indicate that immunosuppressive and anti-TNF treatment for more than 1 year reduce the risk of transitioning from stage B1 to pB3 in the long-term run.